755 100% Svr4 and Favorable Safety of Abt-493 + Abt-530 Administered for 12 Weeks in Non-Cirrhotic Patients With Genotypes 4, 5, or 6 Infection (Surveyor-I)
Authors:
- Edward GaneEGEdward Gane
- Jacob LalezariJLJacob Lalezari
- Armen AsatryanAAArmen Asatryan
- Susan GreenbloomSGSusan Greenbloom
- Tarek I. HassaneinTHTarek I. Hassanein
- Teresa NgTNTeresa Ng
- Ran LiuRLRan Liu
- Chih-Wei LinCLChih-Wei Lin
- Jens KortJKJens Kort
- Federico MensaFMFederico Mensa
- 1 April 2016
- journal article
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1047